ICON Public (NASDAQ:ICLR) Hits New 1-Year Low – What’s Next?

ICON Public Limited (NASDAQ:ICLR) reached a new 52-week low during mid-day trading on Wednesday . The stock traded as low as $208.34 and last traded at $208.69, with a volume of 175296 shares changing hands. The stock had previously closed at $212.27.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on ICLR shares. StockNews.com lowered ICON Public from a “buy” rating to a “hold” rating in a research note on Thursday, September 19th. Barclays dropped their price target on ICON Public from $330.00 to $275.00 and set an “overweight” rating on the stock in a research note on Friday, October 25th. Redburn Atlantic started coverage on shares of ICON Public in a research note on Monday, October 14th. They set a “neutral” rating and a $311.00 price objective for the company. The Goldman Sachs Group dropped their target price on shares of ICON Public from $370.00 to $280.00 and set a “buy” rating on the stock in a research report on Friday, October 25th. Finally, Evercore ISI cut their price target on shares of ICON Public from $360.00 to $350.00 and set an “outperform” rating on the stock in a report on Tuesday, October 8th. Four equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, ICON Public presently has an average rating of “Moderate Buy” and a consensus price target of $304.27.

ICON Public Stock Down 3.1 %

The company has a quick ratio of 1.34, a current ratio of 1.34 and a debt-to-equity ratio of 0.35. The company has a market cap of $16.96 billion, a P/E ratio of 23.04, a PEG ratio of 1.57 and a beta of 1.25. The firm has a fifty day moving average price of $273.62 and a 200 day moving average price of $303.50.

ICON Public (NASDAQ:ICLR) last issued its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $3.35 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.72 by ($0.37). The firm had revenue of $2.03 billion for the quarter, compared to analyst estimates of $2.13 billion. ICON Public had a net margin of 9.00% and a return on equity of 11.91%. The firm’s revenue for the quarter was down 1.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $3.10 EPS. Equities research analysts forecast that ICON Public Limited will post 13.43 earnings per share for the current year.

Institutional Investors Weigh In On ICON Public

Hedge funds have recently modified their holdings of the business. Ashton Thomas Private Wealth LLC bought a new position in ICON Public during the 2nd quarter worth $54,000. ORG Partners LLC acquired a new position in ICON Public in the 2nd quarter valued at approximately $59,000. GAMMA Investing LLC grew its stake in shares of ICON Public by 50.0% in the second quarter. GAMMA Investing LLC now owns 261 shares of the medical research company’s stock worth $82,000 after purchasing an additional 87 shares during the last quarter. EverSource Wealth Advisors LLC grew its stake in shares of ICON Public by 17.4% in the 1st quarter. EverSource Wealth Advisors LLC now owns 283 shares of the medical research company’s stock valued at $95,000 after buying an additional 42 shares during the period. Finally, Whittier Trust Co. of Nevada Inc. raised its stake in ICON Public by 119.6% during the 2nd quarter. Whittier Trust Co. of Nevada Inc. now owns 415 shares of the medical research company’s stock worth $130,000 after buying an additional 226 shares during the period. Institutional investors and hedge funds own 95.61% of the company’s stock.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.